Abstract
Background
Gemcitabine is an efficacious cytotoxic agent used in the treatment of unresectable pancreatic carcinoma (PC). Recently, gemcitabine resistance has been associated with the ribonucleotide reductase subunit M2 (RRM2). In this prospective study, we hypothesized that RRM2 expression in PC biopsy specimens would be a significant predictor of outcome.
Methods
RRM2 mRNA expression in 35 endoscopic ultrasonography-guided fine needle aspiration biopsy (EUS-FNAB) samples was quantified using real-time quantitative reverse transcription-polymerase chain reaction.
Results
Thirty-one of 35 biopsy specimens could be assessed for RRM2 expression levels. The mean RRM2 expression relative to glyceraldehyde-3-phosphate dehydrogenase was 0.248 (range, 0.00739 to 0.858). Eighteen patients (64.5%) had low RRM2 levels, and 13 patients (35.5%) had high RRM2 levels with a cutoff of 0.1. The median survival was 8.8 months for patients with low RRM2 levels and 5.0 months for patients with high levels (P < 0.05). In the low RRM2 expression group, a complete response (CR) was observed in one patient, and a partial response (PR) was observed in eight patients. In contrast, in the high RRM2 expression group, PR was observed in one patient, and CR was not observed. The overall response rate between the high and low expression groups was significantly different (50.0% vs. 7.7%, P < 0.05).
Conclusions
RRM2 mRNA expression of EUS-FNAB specimens is a key predictive marker of survival in gemcitabine-treated patients with PC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
InstitutionalAuthorNameThe Editorial Board of the Cancer Statistics in Japan (2001) Cancer Statistics in Japan Foundation for Promotion of Cancer Research Tokyo
RT Greenlee MB Hill-Harmon TM Thun (2001) ArticleTitleCancer statistics 2001 CA Cancer J Clin 51 15–36 Occurrence Handle11577478 Occurrence Handle1:STN:280:DC%2BD3MrjtFGisg%3D%3D Occurrence Handle10.3322/canjclin.51.1.15
AM Storniolo NH Enas CA Brown M Voi ML Rothenberg R Schilsky (1999) ArticleTitleAn investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma Cancer 85 1261–8 Occurrence Handle10189130 Occurrence Handle10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T Occurrence Handle1:CAS:528:DyaK1MXitVequ70%3D
YG Goan B Zhou E Hu S Mi Y Yen (1999) ArticleTitleOverexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line Cancer Res 59 4204–7 Occurrence Handle10485455 Occurrence Handle1:CAS:528:DyaK1MXlvVSnu7o%3D
LM Nutter Y Cheng (1989) Nature and properties of mammalian ribonucleotide diphosphate reductase JG Cory AH Cory (Eds) Inhibitors of ribonucleotide diphosphate reductase activity Pergamon Press New York 37–54
S Eriksson DW Martin SuffixJr (1981) ArticleTitleRibonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2 J Bio Chem 256 9436–40 Occurrence Handle1:CAS:528:DyaL3MXls1KktL8%3D
MS Duxbury H Ito MJ Zinner SW Ashley EE Whang (2003) ArticleTitleRNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine Oncogene 8 1–10
MJ Wiersema P Vilmann M Giovannini KJ Chang LM Wiersema (1997) ArticleTitleEndosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment Gastroenterology 112 1087–95 Occurrence Handle9097990 Occurrence Handle1:STN:280:DyaK2s3lt1Chsw%3D%3D Occurrence Handle10.1016/S0016-5085(97)70164-1
KJ Chang PM Nguyen RA Erickson TE Durban KD Katz (1997) ArticleTitleThe clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma Gastrointest Endosc 45 387–93 Occurrence Handle9165320 Occurrence Handle10.1016/S0016-5107(97)70149-4 Occurrence Handle1:STN:280:DyaK2szgvVSqtg%3D%3D
M Tada Y Komatsu T Kawabe N Sasahira H Isayama N Toda et al. (2002) ArticleTitleQuantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor Am J Gastroenterol 97 2263–70 Occurrence Handle12358243 Occurrence Handle10.1111/j.1572-0241.2002.05980.x Occurrence Handle1:CAS:528:DC%2BD38XotV2lu7k%3D
T Itoi K Takei A Sofuni F Itokawa T Tsuchiya T Kurihara et al. (2005) ArticleTitleImmunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses Oncol Rep 13 229–34 Occurrence Handle15643503 Occurrence Handle1:CAS:528:DC%2BD2MXhsVGrtb8%3D
Exocrine pancreas. In: American Joint Committee on Cancer, editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 157–64
HA Burris Suffix3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano et al. (1977) ArticleTitleImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403–13
M Hidalgo D Castellano L Paz-Ares C Gravalos M Diaz-Puente R Hitt et al. (1999) ArticleTitlePhase I–II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer J Clin Oncol 17 585–92 Occurrence Handle10080603 Occurrence Handle1:CAS:528:DyaK1MXht1Wmu70%3D
W Scheithauer GV Kornek M Raderer M Hejna J Valencak J Miholic et al. (1999) ArticleTitlePhase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma Br J Cancer 80 1797–802 Occurrence Handle10468299 Occurrence Handle10.1038/sj.bjc.6690600 Occurrence Handle1:CAS:528:DyaK1MXlvFGntbc%3D
V Heinemann H Wilke HG Mergenthaler M Clemens H Konig HJ Illiger et al. (2000) ArticleTitleGemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Ann Oncol 11 1399–403 Occurrence Handle11142479 Occurrence Handle10.1023/A:1026595525977 Occurrence Handle1:STN:280:DC%2BD3M7lt12rtw%3D%3D
CM Rocha Lima MR Green R Rotche WH Miller SuffixJr GM Jeffrey LA Cisar et al. (2004) ArticleTitleIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776–83 Occurrence Handle15365074 Occurrence Handle10.1200/JCO.2004.12.082 Occurrence Handle1:CAS:528:DC%2BD2cXhtVCitb%2FO
E van Cutsem H Van de Velde P Karasek H Oettle WL Vervenne A Szawlowski et al. (2004) ArticleTitlePhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 1430–8 Occurrence Handle15084616 Occurrence Handle10.1200/JCO.2004.10.112 Occurrence Handle1:CAS:528:DC%2BD2cXpt1yjur0%3D
G Bepler S Sharma A Cantor A Gautam E Haura G Simon et al. (2004) ArticleTitleRRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer J Clin Oncol 22 1878–85 Occurrence Handle15143080 Occurrence Handle10.1200/JCO.2004.12.002 Occurrence Handle1:CAS:528:DC%2BD2cXptlCksr0%3D
R Rosell KD Danenberg V Alberola G Bepler JJ Sanchez C Camps et al. (2004) ArticleTitleRibonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 1318–25 Occurrence Handle14977831 Occurrence Handle10.1158/1078-0432.CCR-03-0156 Occurrence Handle1:CAS:528:DC%2BD2cXhsVCqu7o%3D
R Rosell G Scagliotti KD Danenberg RV Lord G Bepler S Novello et al. (2003) ArticleTitleTranscripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 3548–53 Occurrence Handle12789263 Occurrence Handle10.1038/sj.onc.1206419 Occurrence Handle1:CAS:528:DC%2BD3sXktlSjtrw%3D
RA Finch M Liu SP Grill WC Rose R Loomis KM Vasquez et al. (2000) ArticleTitleTriapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 983–91 Occurrence Handle10692563 Occurrence Handle10.1016/S0006-2952(99)00419-0 Occurrence Handle1:CAS:528:DC%2BD3cXht1Ohu7s%3D
S Wadler D Makower C Clairmont P Lambert K Fehn M Sznol (2004) ArticleTitlePhase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion J Clin Oncol 22 1553–63 Occurrence Handle15117978 Occurrence Handle10.1200/JCO.2004.07.158 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWmur4%3D
Y Yen K Margolin J Doroshow M Fishman B Johnson C Clairmont et al. (2004) ArticleTitleA phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer Cancer Chemother Pharmacol 54 331–42 Occurrence Handle15148626 Occurrence Handle10.1007/s00280-004-0821-2 Occurrence Handle1:CAS:528:DC%2BD2cXntV2htrs%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Itoi, T., Sofuni, A., Fukushima, N. et al. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 42, 389–394 (2007). https://doi.org/10.1007/s00535-007-2017-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-007-2017-0